Hamaji Masatsugu, Kawaguchi Atsushi, Omasa Mitsugu, Nakagawa Tatsuo, Sumitomo Ryota, Huang Cheng-Long, Fujinaga Takuji, Ikeda Masaki, Shoji Tsuyoshi, Katakura Hiromichi, Motoyama Hideki, Menju Toshi, Aoyama Akihiro, Sato Toshihiko, Chen-Yoshikawa Toyofumi Fengshi, Sonobe Makoto, Date Hiroshi
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Center for Comprehensive Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):375-379. doi: 10.1093/icvts/ivy260.
Previous studies have suggested that a second malignancy often develops after resection of thymoma; however, it remains unknown whether this is applicable to thymic carcinoma.
A retrospective chart review was performed based on our multi-institutional database of resected thymic epithelial tumours between 1991 and 2016. A second malignancy was defined as newly diagnosed after thymic tumour resection. The cumulative incidence of and related death from a second malignancy after thymic and neuroendocrine carcinoma resections were estimated using a competing risk model and were compared to those of patients undergoing a thymoma resection.
Two hundred and thirty-eight patients were identified (thymic carcinoma 59; thymoma 179). A second malignancy developed in 1 patient (1.7%) with thymic carcinoma and in 17 patients (9.5%) with thymoma. Deaths from second malignancies were noted in 7 patients with thymoma. There was a tendency towards a lower cumulative incidence of and a lower cumulative death from a second malignancy after thymic carcinoma resection (P = 0.139 and P = 0.20, respectively) than after thymoma resection. The cumulative incidence of a second malignancy in patients with thymic carcinoma was 2.8% at 5 years and at 10 years (8.0% at 5 years and 11.8% at 10 years in patients with thymoma).
After resection of thymic and thymic neuroendocrine carcinoma, the probability of developing a second malignancy, as well as mortality from a second malignancy, is very low. A prospective study with a larger sample size is required to validate our results.
既往研究提示,胸腺瘤切除术后常发生第二原发性恶性肿瘤;然而,这是否适用于胸腺癌仍不清楚。
基于我们1991年至2016年间多机构切除的胸腺上皮肿瘤数据库进行回顾性图表审查。第二原发性恶性肿瘤定义为胸腺肿瘤切除术后新诊断的肿瘤。使用竞争风险模型估计胸腺和神经内分泌癌切除术后第二原发性恶性肿瘤的累积发病率及相关死亡率,并与胸腺瘤切除患者的发病率和死亡率进行比较。
共纳入238例患者(胸腺癌59例;胸腺瘤179例)。1例(1.7%)胸腺癌患者发生第二原发性恶性肿瘤,17例(9.5%)胸腺瘤患者发生第二原发性恶性肿瘤。7例胸腺瘤患者死于第二原发性恶性肿瘤。与胸腺瘤切除术后相比,胸腺癌切除术后第二原发性恶性肿瘤的累积发病率和累积死亡率有降低趋势(分别为P = 0.139和P = 0.20)。胸腺癌患者第二原发性恶性肿瘤的累积发病率在5年时为2.8%,10年时为2.8%(胸腺瘤患者5年时为8.0%,10年时为11.8%)。
胸腺和胸腺神经内分泌癌切除术后发生第二原发性恶性肿瘤的概率以及第二原发性恶性肿瘤导致的死亡率非常低。需要进行更大样本量的前瞻性研究来验证我们的结果。